We are live on ! Find out more
BNTX icon

BioNTech

252 hedge funds and large institutions have $4.05B invested in BioNTech in 2023 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 81 increasing their positions, 85 reducing their positions, and 54 closing their positions.

New
Increased
Maintained
Reduced
Closed

5% less repeat investments, than reductions

Existing positions increased: 81 | Existing positions reduced: 85

1.1% less ownership

Funds ownership: 16.52%15.42% (-1.1%)

10% less funds holding

Funds holding: 281252 (-29)

17% less capital invested

Capital invested by funds: $4.88B → $4.05B (-$825M)

31% less call options, than puts

Call options by funds: $201M | Put options by funds: $291M

33% less funds holding in top 10

Funds holding in top 10: 64 (-2)

52% less first-time investments, than exits

New positions opened: 26 | Existing positions closed: 54

Holders
252
Holders Change
-29
Holders Change %
-10.32%
% of All Funds
3.95%
Holding in Top 10
4
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-33.33%
% of All Funds
0.06%
New
26
Increased
81
Reduced
85
Closed
54
Calls
$201M
Puts
$291M
Net Calls
-$90M
Net Calls Change
+$99.2M

BNTX Hedge Fund Activity: Q2 2023 in Review

252 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in BioNTech (BNTX) for Q2 2023, worth a combined $4.05B — down 17% from $4.88B a quarter earlier.

Sellers outnumbered buyers: 54 funds closed out of BNTX and 26 opened new positions — a net loss of 28 holders — while 85 trimmed existing stakes and 81 added.

The largest buyer was Citadel Advisors, adding an estimated $21.1M. The largest seller was Envestnet Asset Management, cutting an estimated $108M.

  • 252 institutional investors held BioNTech (BNTX) as of Q2 2023, down from 281 in Q1 2023.
  • Funds reported $4.05B of BioNTech stock for Q2 2023, down 17% quarter-over-quarter.
  • 26 funds opened new BioNTech positions in Q2 2023 and 54 closed out, a net change of -28 holders.
  • The largest BioNTech buyer in Q2 2023 was Citadel Advisors, an estimated $21.1M added.
  • The largest BioNTech seller in Q2 2023 was Envestnet Asset Management, an estimated $108M sold.

Based on aggregated 13F filings for Q2 2023.